Educational corner

This manual has been prepared by a team of experts with extensive experience in the clinical application of selective granulocyte and monocyte apheresis (GMA). Its purpose is to offer a practical, clear, and concise guide that addresses the key aspects for the proper indication, execution, and optimization of the procedure. It is intended as a […]

Overall course objective: Update healthcare professionals with an interest in inflammatory bowel disease (IBD) on the use of selective granulocyte and monocyte apheresis with Adacolumn® as an adjuvant therapy in its management. Understand the immunomodulatory mechanism of action of Adacolumn® and its scientific basis in controlling intestinal inflammation, as well as to identify the profiles […]

Dr. Rodríguez-Lago shares existing evidence of the crucial role played by innate immunity in the pathogenesis of Inflammatory Bowel Disease (IBD), as well as in the failure of advanced therapies such as biologic drugs and small molecules. Hence, the combined use of granulocyte and monocyte apheresis (GMA, Adacolumn®) targeting mainly innate IBD trigger cells, such […]

Specific considerations must be considered in the treatment of children and adolescents with IBD. Thus, GMA could play an important role in the treatment of some specific pediatric IBD patients in whom reinforcement, safer or longer-term outcomes are needed. In this webinar, Dr. J.M. de Carpi makes an exhaustive review of the rationale for the […]

The main objectives of this webinar are: clarify what is needed to have the best treatment outcome for IBD patients, how to help them maintain control of their disease and how Adacolumn’s mechanism of action might contribute to achieving both, alone or in combination with other therapies. Dr. Alessandro Mazzoni. (A.O.U. Pisana) Dra. Irene Bianco. […]

Source vidéo: La Lettre de L’Hépato Gastroentérologue, EDIMARK France.

Source vidéo: La Lettre de L’Hépato Gastroentérologue, EDIMARK France.

The paediatric inflammatory bowel disease (IBD) can cause malnutrition and growth retardation. Patients with IBD will require life-long treatment but can be limited by the potential adverse events of corticosteroids and anti-TNF agents in children as well as secondary loss of response (LoR) and drug dependence can occur at some time during the lifetime. Experience […]

Source vidéo: La Lettre de L’Hépato Gastroentérologue, EDIMARK France.

Unique considerations when treating children and adolescents with IBD include attention to the effects and risks of the treatments on growth and development, bone health, and psychosocial functioning. New alternatives of treatment still are needed in this context for safer and longer outcomes. The benefits of using steroids, immunosuppressants or biologics need to be carefully […]